Overview of Sirolimus
Sirolimus, also known as Rapamycin, is a macrolide compound with strong immunosuppressive and antiproliferative properties. It was first discovered as a natural product produced by Streptomyces hygroscopicus, a soil bacterium found on Easter Island (Rapa Nui). Sirolimus (CAS Number: 53123-88-9) has since become a key pharmaceutical ingredient widely used in organ transplantation, drug-eluting stents, and cancer research.
Chemical and Physical Properties
Chemical Name: Sirolimus
Synonyms: Rapamycin
CAS Number: 53123-88-9
Molecular Formula: C₅₁H₇₉NO₁₃
Molecular Weight: 914.17 g/mol
Appearance: White to off-white crystalline powder
Solubility: Soluble in ethanol, methanol, chloroform; slightly soluble in water
Sirolimus is a macrocyclic lactone with a complex molecular structure, contributing to its potent biological activity and stability in various formulations.
Mechanism of Action
Sirolimus functions primarily as an mTOR (mammalian target of rapamycin) inhibitor. By binding to the intracellular protein FKBP-12, Sirolimus forms a complex that inhibits mTOR, a central regulator of cell growth, proliferation, and survival.
This inhibition results in:
Suppression of T-cell activation and proliferation, reducing immune responses.
Inhibition of smooth muscle cell proliferation, preventing restenosis in stented arteries.
Regulation of autophagy and metabolism, influencing longevity and disease resistance.
Key Applications
1. Organ Transplantation
Sirolimus is widely used to prevent organ rejection after kidney, liver, or heart transplantation. It helps maintain graft function by suppressing immune activity without the nephrotoxic side effects commonly seen in calcineurin inhibitors.
2. Drug-Eluting Stents (DES)
In cardiology, Sirolimus is a critical coating component for drug-eluting stents. It prevents restenosis (re-narrowing of blood vessels) by inhibiting smooth muscle cell proliferation, thus improving long-term stent performance.
3. Oncology and Research
Due to its mTOR-inhibiting and antiproliferative properties, Sirolimus is being studied as a potential anticancer agent in various tumors, including renal cell carcinoma and breast cancer. It is also explored in anti-aging and metabolic research, given its ability to modulate cellular growth and lifespan.
Advantages and Clinical Benefits
Potent immunosuppressive activity with low nephrotoxicity
Effective anti-proliferative and anti-inflammatory effects
Enhances long-term graft survival
Plays a role in metabolic regulation and cellular longevity
Storage and Stability
Sirolimus should be stored in a cool, dry, and dark environment, typically at temperatures below 25°C. It should be protected from light and moisture to preserve its chemical stability and potency.
Safety and Handling
As a potent bioactive compound, Sirolimus should be handled under standard laboratory safety procedures. Avoid inhalation, ingestion, and skin contact. Appropriate protective equipment (gloves, goggles, lab coat) should be used during handling.
Global Market and Industry Use
Sirolimus is a valuable active pharmaceutical ingredient (API) in the immunosuppressant and cardiovascular drug markets. Its analogs, such as Everolimus and Temsirolimus, have expanded its clinical reach. Increasing R&D investments in mTOR-targeted therapies continue to drive demand for Sirolimus across pharmaceutical and research industries.
Conclusion
Sirolimus (CAS 53123-88-9) is a groundbreaking compound that bridges immunology, oncology, and cardiovascular medicine. As an mTOR inhibitor, it continues to play a vital role in transplantation medicine, stent technology, and cutting-edge biomedical research. With its versatile applications and proven efficacy, Sirolimus remains a cornerstone molecule in modern pharmacology.